Rosen Law Firm reminds purchasers of Erasca, Inc. common stock between January 14, 2025 and April 26, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Erasca, along with its CEO and CFO, made false and misleading statements about its lead oncology drug candidate ERAS-0015, touting it as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' competing drug candidate RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis. Investors with losses in excess of $100,000 are encouraged to secure counsel. To join the Erasca class action, go to https://rosenlegal.com/cases/erasca-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026.
Erasca IncSecurities class action lawsuit alleges false and misleading statements about lead drug candidate, exposing company to legal and reputational risk.
Revolution Medicines IncMentioned only as a comparator for Erasca's drug candidate; no direct impact from the lawsuit.